Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Whittier Trust Co. of Nevada Inc.

Whittier Trust Co. of Nevada Inc. lessened its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 29.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 118 shares of the biopharmaceutical company’s stock after selling 49 shares during the quarter. Whittier Trust Co. of Nevada Inc.’s holdings in Regeneron Pharmaceuticals were worth $84,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in REGN. FSA Wealth Management LLC acquired a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at $26,000. OFI Invest Asset Management acquired a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at $28,000. Rakuten Securities Inc. boosted its holdings in shares of Regeneron Pharmaceuticals by 62.5% in the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 15 shares during the last quarter. Avalon Trust Co acquired a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at $36,000. Finally, Private Wealth Management Group LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 260.0% in the 4th quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company’s stock valued at $38,000 after purchasing an additional 39 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 0.6 %

NASDAQ REGN opened at $658.48 on Monday. Regeneron Pharmaceuticals, Inc. has a one year low of $642.00 and a one year high of $1,211.20. The company has a 50-day simple moving average of $689.43 and a 200-day simple moving average of $813.15. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The firm has a market capitalization of $71.99 billion, a PE ratio of 17.20, a price-to-earnings-growth ratio of 2.34 and a beta of 0.27.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same period in the previous year, the business posted $11.86 EPS. The company’s quarterly revenue was up 10.3% on a year-over-year basis. On average, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were issued a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.53%. The ex-dividend date was Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 2.30%.

Analyst Ratings Changes

REGN has been the topic of a number of research reports. UBS Group downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their target price for the company from $1,130.00 to $738.00 in a research note on Thursday, January 16th. Wells Fargo & Company cut their target price on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a research note on Friday, January 10th. Leerink Partnrs raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 5th. Piper Sandler cut their target price on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating on the stock in a research note on Monday, January 27th. Finally, Citigroup cut their target price on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $973.13.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.